Our History of Advancing Science
Established in 2003 by world-renowned researchers, our history is deeply rooted in science and our research and development efforts are focused on disease areas with significant unmet need for new treatment options to help improve the lives of patients.
Radius initiated the Phase 3 ATOM (Abaloparatide Treatment for Osteoporosis in Males) study of abaloparatide injection for the treatment of osteoporosis in men.
Radius announced scale-up and commercial supply agreement with 3M to exclusively manufacture commercial supplies of abaloparatide patch.
Radius provided update on data from the clinical studies of elacestrant during the 2017 San Antonio Breast Cancer Symposium (SABCS).
U.S. Food and Drug Administration granted Fast Track designation for elacestrant.
Radius initiated Phase 1 study of RAD140, an internally developed selective androgen receptor modulator (SARM) undergoing clinical evaluation for the treatment of hormone receptor positive breast cancer.
Jesper Høiland appointed President and Chief Executive Officer.
Radius presented update on data from ongoing study of elacestrant at the American Society of Clinical Oncology (ASCO) Meeting.
TYMLOS® (abaloparatide) injection was approved on April 28, 2017 by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Radius presented data from two ongoing Phase 1 studies of elacestrant in patients with estrogen receptor positive (ER+) breast cancer at the San Antonio Breast Cancer Symposium (SABCS).
Radius’ NDA for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis accepted for filing by the U.S. Food and Drug Administration.
Radius commenced a Phase 1 FES-PET study in patients with metastatic breast cancer in the European Union, which includes the use of FES-PET imaging to assess estrogen receptor occupancy in tumor lesions following elacestrant treatment.
Radius presented data from the first six months of ACTIVExtend trial during the American Society for Bone and Mineral Research (ASBMR) Annual Meeting.
Radius presented data from the Phase 3 ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) trial during the Endocrine Society (ENDO) Annual Meeting.
Radius commenced elacestrant Phase 1 study in postmenopausal women with ER+ and HER2- advanced breast cancer in the United States.
Radius completed successful IPO.
Abaloparatide-SC Phase 3 extension study (ACTIVExtend) commenced.
Radius and 3M Drug Delivery Systems announced exclusive agreement for development of abaloparatide patch.
Radius initiated Phase 2 Study of Abaloparatide-patch for the Treatment of Postmenopausal Osteoporosis.
Abaloparatide-SC Phase 3 ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) trial initiated in postmenopausal women with osteoporosis.
Abaloparatide-SC Phase 2 trial initiated in postmenopausal women with osteoporosis.
Radius in-licensed elacestrant (RAD1901), a selective estrogen receptor degrader (SERD).
Nuvios became Radius Health, Inc.
Nuvios in-licensed abaloparatide.